| Date | Title | Description |
| 27.10.2023 | Mogrify – extends Series A financing to $46m USD | Parkwalk is pleased to announce that portfolio company, Mogrify, have extended their Series A financing to $46m USD. The University of Cambridge and University of Bristol spinout is enabling the next generation of gene sequencing and gene-r... |
| 03.10.2023 | UK-based Mogrify raises an additional USD 10 million extending Series A funding to USD 46 million | Cambridge, United Kingdom-based biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, Mogrify raised an additional USD 10 million in funding. The company announced the investm... |
| 02.10.2023 | Mogrify extends Series A financing to $46 million USD | Cambridge, UK: Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announces an additional $10 million USD closing of its Series A financing, bringing the total r... |
| 02.10.2023 | Mogrify Raises Additional $10M in Series A Funding | Mogrify, a Cambridge, UK-based biopharmaceutical company advancing in vivo reprogramming therapies, raised additional $10M in Series A funding.
The round, which brought total amount to $46M in the round, was led by Astellas Venture Manageme... |
| 02.11.2021 | Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor | Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor
02-11-2021
Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies a... |
| 04.05.2021 | Mogrify : Completes Series A Financing Totaling $33 Million USD | Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second closing of its Series A financing o... |
| 04.05.2021 | Mogrify raises $17m investment led by Parkwalk Advisors | - |
| 04.05.2021 | Mogrify Raises 17M in Second Series A Close | Mogrify Limited, a Cambridge, England, UK-based biopharmaceutical company, held the second closed of Series A financing of $17m, bringing the total raised to $33m in this round.
This second close of the Series A was led by Parkwalk Advisors... |
| 26.03.2021 | Double win for Mogrify at CambridgeshireLive Business Excellence Awards 2020 | Double win for Mogrify at CambridgeshireLive Business Excellence Awards 2020
26-03-2021
Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards... |
| 11.01.2021 | Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology | Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
11-01-2021
Mogrify Limited, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapi... |
| 02.11.2020 | Mogrify expands Scientific Advisory Board | Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.
Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vi... |
| 02.11.2020 | Mogrify expands Scientific Advisory Board | Mogrify expands Scientific Advisory Board
02-11-2020
Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.
Mogrify Limited (Mogrify®), a UK... |
| 18.09.2020 | Business Weekly Awards 2020 | Frontier Developments named Business of the Year
Article by Tony Quested | Business Weekly
Frontier Developments, Cambridge’s world-leading video games developer is today unveiled as Business of the Year in the toughest competition in 30 ye... |
| 12.03.2020 | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards
12-03-2020
Cofinitive are delighted to announce that they have been shortlisted in the upcoming Business Weekly Awards.
The shortlist has listed us as “a growing team of comm... |
| 28.01.2020 | Mogrify awarded $1.1M additional funding from SBRI Healthcare | Mogrify awarded $1.1M additional funding from SBRI Healthcare
28-01-2020
Mogrify Ltd (Mogrify™), a UK company aiming to transform the development of cell therapies, today announced that it has secured $1.1M of additional funding from SBRI H... |
| 23.12.2019 | ‘Tis the season to be jolly. And cofinitive has lots to be jolly about after a great Q4 | ‘Tis the season to be jolly. And cofinitive has lots to be jolly about after a great Q4
23-12-2019
Cofinitive writes: It's been a busy time for the cofinitive team. Take a look at some of our highlights from the last three months of 2019.
F... |
| 06.12.2019 | Mogrify wins Innovation Award and Dr Jane Osbourn OBE receives Lifetime Achievement Award at Scrip Awards 2019 | Mogrify Ltd, a UK company aiming to transform the development of cell therapies, received MSD’s Innovation Award at the 15th Annual Scrip Awards, and the Lifetime Achievement Award was presented to Dr Jane Osbourn, OBE, Chair at Mogrify.
Th... |
| 06.12.2019 | Mogrify wins Innovation Award and Dr Jane Osbourn OBE receives Lifetime Achievement Award at Scrip Awards 2019 | Mogrify wins Innovation Award and Dr Jane Osbourn OBE receives Lifetime Achievement Award at Scrip Awards 2019
06-12-2019
Mogrify Ltd, a UK company aiming to transform the development of cell therapies, received MSD’s Innovation Award at th... |
| 21.10.2019 | Hello autumn, farewell summer | Hello autumn, farewell summer
21-10-2019
Things show no sign of slowing down for cofinitive as we head into the final few months of 2019...
The team writes:
It’s time for our Autumn update where we look back on the last quarter. And let’s s... |
| 15.10.2019 | Daily funding roundup - October 14th, 2019 | Redesign Science has raised $2M; Latent AI secured $3.5M; Mogrify landed $16M
Redesign Science: Redesign Science’s platform is working on to advance new small molecule therapeutics. Redesign Science has raised $2 million in seed funding led... |
| 14.10.2019 | Cambridge-based Mogrify raises additional €14.5 million to advance its mission to transform the development of life-saving cell therapies | Cambridge-based Mogrify is a company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding round.
The company raised €14.5 million in this round, bringing the total inve... |
| 14.10.2019 | UK-based biotech startup Mogrify raises additional $16 million to transform the development of life-saving cell therapies | Cell therapy development and manufacturing is estimated to represent a $30 billion USD market opportunity and is rapidly growing (CAGR +30%). Mogrify is a UK-based biotech startup aiming to transform the development of life-saving cell ther... |
| 14.10.2019 | Mogrify raises $16m Series A Funding Round | - |
| 14.10.2019 | Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies | Mogrify Ltd, a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over ... |
| 14.10.2019 | Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies | Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies
14-10-2019
Mogrify Ltd, a UK company aiming to transform the development of life-saving cell therapies, today announced ... |
| 14.10.2019 | UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon | Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A.
The raise from investors Ahren Innova... |
| 14.10.2019 | Mogrify Raises $16M in Funding | Mogrify Ltd, a Cambridge, UK-based company advancing life-saving cell therapies, held the initial close of its Series A funding raising $16m.
The round, which brought total funding raised by the company to date to over $20m, was led by exis... |
| 14.10.2019 | Top tech startup news for today, Monday, October 14, 2019 | Good morning! Below are some of the top tech startup news for today, Monday, October 14, 2019.
WeWork opens new locations at breakneck speed despite cash-burn concerns. In an effort to generate new revenue, real estate startup WeWork has o... |
| 14.10.2019 | UK medtech Mogrify raises $20 million to develop life-saving cell therapies | Cambridge-based Mogrify, a medtech company developing proprietary technology that transforms cell research and patient treatments, has announced $16 million in Series A funding. The round was led by the original lead investor, Ahren Innovat... |
| 01.04.2019 | Mogrify Subsidiary Chondrogenix Secures Funding from SBRI Healthcare | Chondrogenix, a wholly owned subsidiary of Mogrify Ltd, a Cambridge, UK-based company innovation development of cell therapies, secured funding from SBRI Healthcare, the NHS England funded initiative championed by the AHSN Network.
The amou... |
| 27.02.2019 | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards
27-02-2019
Cofinitive is delighted to announce it has been shortlisted among the brightest and best of elite Cambridge-based companies in the upcoming B... |
| 20.02.2019 | Biotech startup Mogrify secures $3.7 million seed funding to accelerate and transform cell therapy via direct cellular conversion | Mogrify, a U.K. based biotech startup aiming to transform the future development of cell therapies, has raised $3.7 million seed funding to market novel IP and cell types generated using its proprietary direct cellular conversion platform, ... |
| 20.02.2019 | Mogrify Raises $3.7M in Seed Funding | Cell Mogrify Ltd, a Cambridge, England, UK-based developer of cell therapies, held the second close on its seed funding, now totalling $3.7m.
The round was led by existing investor Ahren Innovation Capital (Ahren), with 24Haymarket and Dr D... |
| 20.02.2019 | Mogrify Raises $3.7mn Seed Funding to Accelerate its Mission to Transform Cell Therapy via Direct Cellular Conversion | - |
| 20.02.2019 | Mogrify raises $3.7m seed funding | - |
| 20.02.2019 | Mogrify raises $3.7m seed funding to transform cell therapy via direct cellular conversion | Cell Mogrify Ltd, a UK company aiming to transform the future development of cell therapies, today announced a second close on its seed funding, bringing the total raised to $3.7 million USD, and the appointment of Darrin M Disley, PhD, DSc... |
| 20.02.2019 | Top startup news for today, Wednesday, February 20, 2019 | Good morning! Here are some of the top technology startup news stories for today, Wednesday, February 20.
SoftBank bets big on real estate with $200 million investment in Clutter at a $600 million valuation. SoftBank has invested $200 mill... |
| 20.02.2019 | Mogrify raises $3.7m seed funding to transform cell therapy via direct cellular conversion | Mogrify raises $3.7m seed funding to transform cell therapy via direct cellular conversion
20-02-2019
Cell Mogrify Ltd, a UK company aiming to transform the future development of cell therapies, today announced a second close on its seed fu... |
| - | Mogrify – closes $16m funding round | Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies. |
| - | Mogrify – closes $17m Series A funding round | Parkwalk are pleased to announce an investment in Mogrify, a Cambridge based cell therapy company. Parkwalk led the $17 million USD funding round round, bringing the total Series A round to $33 million USD. |
